[go: up one dir, main page]

BRPI0819571A2 - "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica" - Google Patents

"método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica"

Info

Publication number
BRPI0819571A2
BRPI0819571A2 BRPI0819571A BRPI0819571A BRPI0819571A2 BR PI0819571 A2 BRPI0819571 A2 BR PI0819571A2 BR PI0819571 A BRPI0819571 A BR PI0819571A BR PI0819571 A BRPI0819571 A BR PI0819571A BR PI0819571 A2 BRPI0819571 A2 BR PI0819571A2
Authority
BR
Brazil
Prior art keywords
emergency contraception
pharmaceutical
pharmaceutical composition
package
contraception
Prior art date
Application number
BRPI0819571A
Other languages
English (en)
Inventor
E Diliberti Charles
Original Assignee
Teva Womenss Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Womenss Health Inc filed Critical Teva Womenss Health Inc
Publication of BRPI0819571A2 publication Critical patent/BRPI0819571A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0819571A 2007-12-20 2008-12-19 "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica" BRPI0819571A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US828707P 2007-12-20 2007-12-20
PCT/US2008/013933 WO2009082478A1 (en) 2007-12-20 2008-12-19 Dosage regimens and pharmaceutical compositions and packages for emergency contraception

Publications (1)

Publication Number Publication Date
BRPI0819571A2 true BRPI0819571A2 (pt) 2019-09-24

Family

ID=40799234

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819571A BRPI0819571A2 (pt) 2007-12-20 2008-12-19 "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica"

Country Status (9)

Country Link
US (1) US20090170823A1 (pt)
EP (1) EP2234491A4 (pt)
JP (2) JP2011507853A (pt)
AU (1) AU2008341138A1 (pt)
BR (1) BRPI0819571A2 (pt)
CA (1) CA2710293A1 (pt)
EA (1) EA201070715A1 (pt)
IL (1) IL206465A0 (pt)
WO (1) WO2009082478A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079245A2 (en) * 2006-12-20 2008-07-03 Duramed Pharmaceuticals, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
FR2937862B1 (fr) * 2008-11-03 2010-11-19 Mohammed Ridha Chakroun Kit contraceptif
US20100155594A1 (en) * 2008-12-23 2010-06-24 Goldman Mildred M Mass spectrometry assay for estrogenic compounds
DK2419108T3 (en) * 2009-04-14 2016-12-05 Hra Pharma Lab A method for on-demand control of conception,
AU2014268779A1 (en) 2013-05-21 2016-01-21 Predictive Therapeutics, LLC Therapeutic and method of use

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684534A (en) * 1985-02-19 1987-08-04 Dynagram Corporation Of America Quick-liquifying, chewable tablet
DK174724B1 (da) 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet
NZ254534A (en) * 1992-07-01 1997-12-19 Ortho Pharma Corp 1,4,5,6-tetrahydro-pyridazine derivatives, preparation and pharmaceutical compositions thereof
DE4344463A1 (de) * 1993-12-22 1995-06-29 Schering Ag Kombinationsprodukt zur Kontrazeption
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
CA2203541A1 (en) * 1994-10-24 1996-05-02 Kristof Chwalisz Competitive progesterone antagonists for demand-oriented female birth control
ZA9510926B (en) * 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
AU2558297A (en) * 1996-05-16 1997-12-05 Gynetics Inc. Emergency contraceptive kit
FR2772617B1 (fr) * 1997-12-19 2001-03-09 Besins Iscovesco Lab Comprime de progesterone et son procede de preparation
US6368625B1 (en) * 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
US6060078A (en) 1998-09-28 2000-05-09 Sae Han Pharm Co., Ltd. Chewable tablet and process for preparation thereof
US6667050B1 (en) * 1999-04-06 2003-12-23 Galen (Chemicals) Limited Chewable oral contraceptive
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6399593B1 (en) * 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6660726B2 (en) 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
HU227198B1 (en) * 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
US20030158432A1 (en) * 2002-01-08 2003-08-21 Leonard Thomas W. Synthesis of a mixture of sulfated estrogens using a sulfur trioxide complex
HRP20040923A2 (en) * 2002-03-11 2004-12-31 Schering Ag 5-{2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino}-phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy
EP1531824A4 (en) * 2002-06-25 2005-09-21 Wyeth Corp CYCLOTHIOCARBAMATIVE DERIVATIVES AS PR MODULATORS AND THEIR USE IN TREATING SKIN DISORDERS
MXPA04012419A (es) * 2002-06-25 2005-04-19 Wyeth Corp Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con la hormona.
TW200404548A (en) 2002-06-25 2004-04-01 Wyeth Corp Pharmaceutical composition containing cyclothiocarbamate derivatives in treatment of hormone-related conditions
WO2004033459A1 (en) * 2002-10-11 2004-04-22 Ligand Pharmaceuticals Incorporated 5-(1',1'-CYCLOALKYL/ALKENYL)METHYLIDENE 1,2-DIHYDRO-5H-CHROMENO[3,4-f]QUINOLINES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
US20060008408A1 (en) * 2002-10-17 2006-01-12 Nexen Nano Tech. Co., Ltd. Fibrous nano-carbon and preparation method thereof
CA2524806C (en) * 2003-05-07 2011-07-12 Akina, Inc. Highly plastic granules for making fast melting tablets
AR047398A1 (es) * 2003-11-24 2006-01-18 Wyeth Corp Acoplamiento cruzado carbono- carbono catalizado por metales de transicion sobre soportes solidos
CA2548822C (en) * 2003-12-08 2015-08-11 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
CN1672685A (zh) * 2004-03-26 2005-09-28 董可娟 一种新的避孕药物
US7399870B2 (en) * 2004-03-30 2008-07-15 Wyeth Synthesis of pyrrole-2-carbonitriles
EP1751081A2 (en) * 2004-04-08 2007-02-14 Wyeth Method for preparing 3-cyclopentyloxy-4-methoxybenzaldehyde
DE602005010065D1 (de) * 2004-04-08 2008-11-13 Wyeth Corp Verfahren zur minimierung von thioamidverunreinigungen
WO2005100346A1 (en) * 2004-04-08 2005-10-27 Wyeth Thioamide derivatives as progesterone receptor modulators
MXPA06012402A (es) 2004-04-27 2007-01-17 Wyeth Corp Carbamato y tiocarbamato biarilos ciclicos que contienen cianopirrol y metodos para preparar los mismos.
PA8631101A1 (es) * 2004-04-27 2006-09-08 Wyeth Corp Proceso de acoplamiento para la generacion de derivados reactivos de pirrol-2-carbonitrilo n-sustituidos con contenido de boro para producir biarilos
WO2005104711A2 (en) * 2004-04-27 2005-11-10 Wyeth Purification of progesterone receptor modulators
JP5288796B2 (ja) * 2004-07-07 2013-09-11 ワイス・エルエルシー 周期的プロゲスチンレジメン及びキット
GT200500183A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
ES2380219T3 (es) * 2004-08-13 2012-05-09 Wyeth Llc Metabolitos, derivados de tanaproget, y sus utilizaciones
EP1781701A2 (en) * 2004-08-20 2007-05-09 Wyeth Progesterone receptor structure
JP4197684B2 (ja) * 2005-03-23 2008-12-17 株式会社東芝 携帯無線機
WO2007030153A2 (en) * 2005-04-28 2007-03-15 Wyeth Compositions containing micronized tanaproget
US7767668B2 (en) 2005-04-28 2010-08-03 Wyeth Llc Micronized tanaproget, compositions, and methods of preparing the same
US7786297B2 (en) * 2005-04-28 2010-08-31 Wyeth Llc Purified form of tanaproget
BRPI0610431A2 (pt) * 2005-04-28 2012-10-23 Wyeth Corp composição farmacêutica, processo para preparar uma composição, cápsula, e, kit farmacêutico
MX2007013469A (es) * 2005-04-28 2008-01-22 Wyeth Corp Forma ii polimorfa de tanaproget.
GT200600179A (es) * 2005-04-29 2006-11-22 Proceso para preparar oxindoles y tio-oxindoles 3,3-disustituidos
KR100733419B1 (ko) * 2005-04-30 2007-06-29 주식회사 하이닉스반도체 내부전원 생성장치
US20060293295A1 (en) * 2005-05-13 2006-12-28 Kai Strothmann Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6S)-tetrahydrofolate
UY29527A1 (es) * 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
EA015155B1 (ru) * 2005-05-26 2011-06-30 Тева Вуменс Хелс, Инк. Дозированные формы для перорального применения, содержащие прогестерон, и способы их изготовления и использования
TW200716137A (en) 2005-06-09 2007-05-01 Wyeth Corp Tanaproget compositions containing ethinyl estradiol
US20100105640A1 (en) * 2005-06-28 2010-04-29 Casper Robert F Aromatase Inhibitors for Emergency Contraception
PE20070182A1 (es) * 2005-07-29 2007-03-06 Wyeth Corp Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
PE20070404A1 (es) * 2005-07-29 2007-05-10 Wyeth Corp Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona
PE20070341A1 (es) * 2005-07-29 2007-04-13 Wyeth Corp Derivados de pirrol como moduladores del receptor de progesterona
AR056048A1 (es) * 2005-09-01 2007-09-12 Tanabe Seiyaku Co Compuesto tiomorfolina y procedimiento para preparar el mismo
US7319152B2 (en) * 2005-09-19 2008-01-15 Wyeth 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators
US20070066628A1 (en) * 2005-09-19 2007-03-22 Wyeth 5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
US20070093548A1 (en) * 2005-10-25 2007-04-26 Wyeth Use of progesterone receptor modulators
US20070213526A1 (en) * 2006-03-07 2007-09-13 Wyeth Purification of progesterone receptor modulators
TW200810231A (en) * 2006-08-11 2008-02-16 Hon Hai Prec Ind Co Ltd Antenna device
WO2008079245A2 (en) * 2006-12-20 2008-07-03 Duramed Pharmaceuticals, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof

Also Published As

Publication number Publication date
AU2008341138A1 (en) 2009-07-02
EP2234491A1 (en) 2010-10-06
WO2009082478A1 (en) 2009-07-02
EA201070715A1 (ru) 2011-02-28
US20090170823A1 (en) 2009-07-02
CA2710293A1 (en) 2009-07-02
IL206465A0 (en) 2010-12-30
EP2234491A4 (en) 2010-12-22
JP2014193918A (ja) 2014-10-09
JP2011507853A (ja) 2011-03-10

Similar Documents

Publication Publication Date Title
BRPI1011815A2 (pt) "composição farmacêutica para a contracepção de emergência"
BRPI1014865A2 (pt) "composição e formulação farmacêutica comreendendo derivados de nitrocatecol, e, método para fabricar uma composição ou formulação farmacêutica"
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0807807A2 (pt) " composição farmacêutica de liberação modificada e um processo para fabricar a mesma ".
BRPI0810928A2 (pt) "composição farmacêutica"
BRPI0818680A2 (pt) composição farmacêutica, preparação farmacêutica, e método para preparar um forma de dosagem oral farmacêutica
BRPI0813201A2 (pt) "composição curável, compósito e método para formar um compósito"
BRPI0815057A2 (pt) Composto, composição farmacêutica, e, método para tratar infecção.
BRPI0720232A2 (pt) Produto de cloridrato de oximorfona, formulação farmacêutica, método para purificar cloridrato de oximorfona, e, produto de cloridrato de oximorfona
BRPI0816513A2 (pt) Composição farmacêutica e método para preparar a suspensão sólida
BRPI0817917A2 (pt) Implemento para cuidado oral, e, método para formar um implemento para cuidado oral
BRPI0808293A2 (pt) "composições para administração nasal"
BRPI0816553A2 (pt) "composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto"
BRPI0916102A2 (pt) "método para a prevenção da hérnia paraestomal, método para preparar uma hérnia paraestomal e dispositivo para preparar ou reduzir a incidência da hérnia paraestomal"
BRPI0914371A2 (pt) "composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo, e produto de combinação"
BRPI0819534A2 (pt) Composição farmacêutica, método para tratar hiv ou aids e método para preparar uma composição farmacêutica, forma de dosagem e composição"
BR112012003462A2 (pt) "composto, composição farmacêutica, e, método para tratar um paciente tendo uma condição mediada pela proteína quinase."
BRPI0916104A2 (pt) "sistema de acondicionamento para sistema cosmético"
EP2199402A4 (en) CYCLOASTRAGENOL MONOGLYCOSIDE, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF
BRPI0903914A2 (pt) Uso de um composto, método para analisar a eficácia de uma composição de liberação prolongada, e, composição farmacêutica.
BRPI0807001A2 (pt) Formulação farmacêutica, e, método para preparação de uma formulação farmacêutica.
PT2231598E (pt) Novos derivados diazéniodiolato, processo para a sua preparação e as composições farmacêuticas que os contenham
BRPI0819571A2 (pt) "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica"
BRPI0906045A2 (pt) "composição farmacêutica para administração nasal"

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.